{"doi":"10.1002/mdc3.70367","title":"High Cerebrospinal <scp>DOPA</scp> Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease","abstract":"BACKGROUND: DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson's disease (PD) biomarker, but its association with nonmotor symptoms is unclear. OBJECTIVES: We aimed to determine if baseline DDC was associated with future cognitive decline in PD. METHODS: We correlated baseline CSF DDC, detected using the proximity extension assay, with Montreal Cognitive Assessment (MoCA) score using longitudinal data from 3 cohorts: Biopark, PPMI, and PDBP. RESULTS: DDC was significantly associated with cognitive decline in both the Biopark cohort (P-value < 0.0001) and the PDBP/PPMI cohorts (P-value < 0.0001). The results were still significant after correcting for levodopa-equivalent daily dose in the Biopark cohort (P-value < 0.0001) and when the analysis was restricted to the de novo subjects, both in Biopark (P-value: 0.0065) and PPMI (P-value<0.0001) cohorts. CONCLUSIONS: CSF DDC is a potential biomarker for the prediction of cognitive decline in PD patients.","journal":"Movement Disorders Clinical Practice","year":2025,"id":524491,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9586,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1121643,"name":"Wojciech Pasławski","orcid":"0000-0003-2141-4547","position":1,"is_corresponding":false},{"id":1219063,"name":"Shervin Khosousi","orcid":null,"position":2,"is_corresponding":false},{"id":1218443,"name":"Ioanna Markaki","orcid":"0000-0003-3328-5746","position":3,"is_corresponding":false},{"id":21711,"name":"Michael A. Nalls","orcid":null,"position":4,"is_corresponding":false},{"id":6975,"name":"Andrew B. Singleton","orcid":null,"position":5,"is_corresponding":false},{"id":252389,"name":"Hirotaka Iwaki","orcid":"0000-0002-8982-7885","position":6,"is_corresponding":false},{"id":279138,"name":"Per Svenningsson","orcid":"0000-0001-6727-3802","position":7,"is_corresponding":false},{"id":373823,"name":"Andrea Sturchio","orcid":"0000-0002-1067-2834","position":0,"is_corresponding":true}],"reference_count":16,"raw_metadata":null,"created_at":"2026-07-19T02:50:12.083054Z","pmid":"40990085","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}